CARCINOMA, TRANSITIONAL CELL
Clinical trials for CARCINOMA, TRANSITIONAL CELL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, TRANSITIONAL CELL trials appear
Sign up with your email to follow new studies for CARCINOMA, TRANSITIONAL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug option for Hard-to-Treat cancers with FGFR3 mutations
Disease control AVAILABLEThis expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …
Matched conditions: CARCINOMA, TRANSITIONAL CELL
Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for bladder cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…
Matched conditions: CARCINOMA, TRANSITIONAL CELL
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC